Medical Marijuana Benefits: Study Reveals Significant and Sustained Improvements in Quality of Life for Patients
A new study published by the American Medical Association (AMA) has highlighted the substantial benefits of medical marijuana, providing “significant improvements” in the quality of life for individuals grappling with chronic pain, insomnia, and other eligible conditions. The study, conducted in Australia and involving 3,148 patients who were prescribed medical cannabis, reveals that marijuana effectively enhances multiple facets of well-being while rare adverse effects were observed. Published in the Journal of the American Medical Association (JAMA) Health Policy, this research underscores the positive impact of medical marijuana on patients’ overall health-related quality of life.
Examining the impact of medical cannabis treatment, researchers from the Swinburne University of Technology, University of Western Australia, and Austin Hospital conducted a retrospective case series analysis. Patients diagnosed with various conditions were asked to rate their wellness in eight categories using a 0-100 scale: general health, bodily pain, physical functioning, physical role limitations, mental health, emotional role limitations, social functioning, and vitality. Throughout 15 follow-ups administered approximately every 45 days, participants who consumed cannabis reported average improvements ranging from 6.6 to 18.31 points on the 100-point scale, depending on the category.
According to the researchers, these findings suggest that patients with a wide range of health conditions may experience improvements in health-related quality of life through medical cannabis treatment. The study further highlights the sustained positive effects over time among patients utilizing medical marijuana.
The study revealed that medical marijuana was commonly prescribed for non-cancer chronic pain (68.6 percent), cancer-related pain (6.0 percent), insomnia (4.8 percent), and anxiety (4.2 percent). The researchers emphasized the increasing prevalence of cannabis use as medicine and the need for clinical evidence incorporating patient-reported outcomes to assess safety and efficacy, considering the diverse range of conditions being treated and the variety of available marijuana products and dose forms.
Despite variations in doses, consumption methods, and cannabinoid profiles of the marijuana products used by patients, the study found that the “estimated treatment effects were very similar.” However, it is important to note that the retrospective case series analysis had limitations due to the absence of a control group, which makes it challenging to generalize the results.
In conclusion, this study adds to the growing body of research supporting the therapeutic potential of medical marijuana. As more states and countries reform their cannabis laws, studies like these provide valuable insights into the benefits of marijuana for patients. Earlier studies have shown improved cognition and reduced pain among cancer patients and individuals undergoing chemotherapy, as well as reductions in prescribed opioids for chronic pain patients. Moreover, state-level cannabis legalization has been associated with reduced opioid prescribing and overdose deaths.
While this study demonstrates a favorable association between medical cannabis treatment and quality of life across diverse conditions, the researchers emphasize the need for further high-quality trials to establish cannabinoid efficacy. Nonetheless, the evidence thus far underscores the positive impact of medical marijuana, offering hope to patients seeking alternative treatments for their health conditions.
